Evidence map›Paper›PMID 35523773›Full record

ArticleNature communications2022

Transmembrane stem cell factor protein therapeutics enhance revascularization in ischemia without mast cell activation.

Eri Takematsu, Miles Massidda, Jeff Auster, Po-Chih Chen, ByungGee Im, Sanjana Srinath, Sophia Canga, Aditya Singh, Marjan Majid, Michael Sherman and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Eri TakematsuDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Miles MassiddaDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.ORCID 0000-0001-7704-9273
Jeff AusterDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Po-Chih ChenDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
ByungGee ImDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Sanjana SrinathDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Sophia CangaDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Aditya SinghDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Marjan MajidDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Michael ShermanDepartment of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Andrew DunnDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Annette GrahamDepartment of Biological and Biomedical Sciences, School of Health and Life Sciences, Glasgow Caledonian University, G4 0BA, Scotland, UK.
Patricia MartinDepartment of Biological and Biomedical Sciences, School of Health and Life Sciences, Glasgow Caledonian University, G4 0BA, Scotland, UK.
Aaron B BakerDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA. abbaker1@gmail.com.ORCID 0000-0002-7991-0183
The University of Texas at Austin · USGlasgow Caledonian University · GBThe University of Texas Medical Branch at Galveston · US

Funding

Mechanical Conditioning of Mesenchymal Stem Cells for Enhanced Recellularized Vascular GraftsR01HL141761 · NHLBI · UNIVERSITY OF TEXAS AT AUSTIN · PI BAKER, AARON BLAIR · 2018 to 2021
$1.6M
Syndecan-1 in Mechanosensing of Engineered MicroenvironmentsR21EB023551 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI BAKER, AARON BLAIR · 2017 to 2018
$450k
Glycocalyx Mimetic Polysaccharides as Therapeutics for AtherosclerosisR21EB024147 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI BAKER, AARON BLAIR · 2017 to 2018
$430k
NHLBI NIH HHS R01 HL141761NIBIB NIH HHS R21 EB023551NIBIB NIH HHS R21 EB024147
6 · The paper itself

Abstract

Stem cell factor (SCF) is a cytokine that regulates hematopoiesis and other biological processes. While clinical treatments using SCF would be highly beneficial, these have been limited by toxicity related to mast cell activation. Transmembrane SCF (tmSCF) has differential activity from soluble SCF and has not been explored as a therapeutic agent. We created novel therapeutics using tmSCF embedded in proteoliposomes or lipid nanodiscs. Mouse models of anaphylaxis and ischemia revealed the tmSCF-based therapies did not activate mast cells and improved the revascularization in the ischemic hind limb. Proteoliposomal tmSCF preferentially acted on endothelial cells to induce angiogenesis while tmSCF nanodiscs had greater activity in inducing stem cell mobilization and recruitment to the site of injury. The type of lipid nanocarrier used altered the relative cellular uptake pathways and signaling in a cell type dependent manner. Overall, we found that tmSCF-based therapies can provide therapeutic benefits without off target effects.

Indexed as

Mast CellsStem Cell FactorAnimalsEndothelial CellsIschemiaLipidsMembrane ProteinsMiceLipidsMembrane ProteinsStem Cell Factor

Identifiers

PMID35523773
PMCPMC9076913
OpenAlexW4229015697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.